If you or a loved one has gallbladder or bile duct cancer, you may be interested in learning more about treatments for it. For a long time, the standard treatment options for this cancer type were ...

Zanidatamab-hrii received FDA accelerated approval for HER2-positive biliary tract cancer, showing a 52% objective response rate in the HERIZON-BTC-01 trial. Biliary tract cancers represent 3% of ...

Acute cholangitis is a severe, bacterial infection of the biliary tract precipitated by an obstruction that often results in systemic inflammation and, in some cases, life‐threatening sepsis. This ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted accelerated approval to zanidatamab-hrii for treatment of adults with previously treated ...

Tovecimig combined with paclitaxel showed a 17.1% response rate in biliary tract cancer, outperforming paclitaxel alone. The COMPANION-002 study reported lower progressive disease rates with tovecimig ...

Please provide your email address to receive an email when new articles are posted on . Researchers reported a 41% confirmed ORR among patients with HER2-positive disease. No patients with ...

Biliary tract infection (BTI) is a disease with high morbidity and mortality, often associated with structural abnormalities such as common bile duct stones and malignant tumors. Although Pseudomonas ...

The approval, which is based on results from the phase 3 KEYNOTE-966 trial, marks the sixth indication for pembrolizumab in gastrointestinal cancer. The FDA has approved pembrolizumab (Keytruda; Merck ...

Extrahepatic cholangiocarcinoma: Genomic variables associated with anatomical location and outcome. This is an ASCO Meeting Abstract from the 2024 ASCO Gastrointestinal Cancers Symposium. This ...